Naringenin inhibited HBx-induced hepatic steatosis by reducing the transcriptional activity of SREBP1c, LXRα, and PPARγ in HBx-transgenic mice and HepG2 cells, indicating that naringenin may be a potential therapeutic drug for inhibiting virus-induced metabolic disorders (46). The gene discussed is SREBF1; the disease is fatty liver disease.